Free Trial

Zymeworks (NASDAQ:ZYME) Shares Gap Down - Here's What Happened

Zymeworks logo with Manufacturing background

Key Points

  • Zymeworks Inc. shares gapped down from a closing price of $14.81 to an opening price of $13.91, with the last traded price at $14.62.
  • Analysts at Wall Street Zen upgraded Zymeworks from a "hold" to a "buy" rating, reflecting a positive outlook despite the recent drop in share price.
  • The company's recent earnings report showed a profit of $0.03 per share, significantly exceeding analyst expectations of a loss, with quarterly revenue reaching $48.73 million.
  • Interested in Zymeworks? Here are five stocks we like better.

Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $14.81, but opened at $13.91. Zymeworks shares last traded at $14.62, with a volume of 87,470 shares.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Zymeworks from a "hold" rating to a "buy" rating in a research note on Sunday, August 17th.

View Our Latest Research Report on ZYME

Zymeworks Stock Performance

The stock has a market cap of $1.13 billion, a P/E ratio of -15.52 and a beta of 1.27.

Zymeworks (NASDAQ:ZYME - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.55. The business had revenue of $48.73 million for the quarter, compared to analyst estimates of $13.66 million. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Read More

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.